Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterised by dyspnea and loss of lung function. METHODS: Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPULSIS(®) trials, we characterized the safety and tolerability of nintedanib 150 mg tw...

Descripción completa

Detalles Bibliográficos
Autores principales: Corte, Tamera, Bonella, Francesco, Crestani, Bruno, Demedts, Maurits G., Richeldi, Luca, Coeck, Carl, Pelling, Katy, Quaresma, Manuel, Lasky, Joseph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581488/
https://www.ncbi.nlm.nih.gov/pubmed/26400368
http://dx.doi.org/10.1186/s12931-015-0276-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581488/
https://www.ncbi.nlm.nih.gov/pubmed/26400368
http://dx.doi.org/10.1186/s12931-015-0276-5

Ejemplares similares